Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Genetic ObesityObesityObesity Due to Melanocortin 4 Receptor Deficiency
Interventions
DRUG

Setmelanotide

RM-493 QD SC injection

Trial Locations (58)

10022

AXIS Clinical Trials, New York

10025

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University, New York

11201

AXIS New York Clinical Trials, Brooklyn

13354

Charité Berlin, Berlin

14203

University at Buffalo, Buffalo

17822

Obesity Institute, Geisinger Clinic, Danville

19104

Childrens Hospital of Philadelphia, Philadelphia

20010

Division of Endocrinology and Diabetes Children's National Hospital, Washington D.C.

20892

NIH Hatfield Clinical Research Center, Bethesda

26504

University General Hospital of Patras, Rio

27612

Wake Research Inc., Raleigh

27705

Duke University Medical Center, Durham

29621

Synexus Clinical Research US, Inc. - Primary Care Associates, PC, Anderson

32610

University of Florida College of Medicine, Gainesville

32804

Florida Hospital, Orlando

33016

AXIS South Florida Clinical Trials, Hialeah

33781

Synexus Clinical Research US, Inc. - St. Petersburg, Pinellas Park

35211

Synexus Clinical Research US, Inc. - Simon Williamson Clinic, PC, Birmingham

37421

Wake Research TN, Chattanooga

38103

Le Bonheur Children's Hospital, Memphis

43016

Synexus Clinical Research US, Inc. - Columbus, Columbus

44311

Synexus Clinical Research US, Inc. - Akron, Akron

45236

Synexus Clinical Research US, Inc. - Cincinnati, Cincinnati

48105

University of Michigan Medicine, Ann Arbor

52621

Edmond and Lily Safra Children's Hospital, Ramat Gan

54449

Marshfield Clinic Research Institute, Marshfield

55905

Precision Medicine for Obesity Research: Gastroenterology & Hepatology Mayo Clinic, Rochester

60602

Synexus Clinical Research US, Inc. - Chicago, Chicago

63110

Washington University St. Louis, St Louis

75012

Hopital Trousseau - Nutrition et Gastroentérologie, Paris

75013

Hopital de la Pitié-Salpêtrière, Paris

75093

Synexus Clinical Research US, Inc. - Plano, Plano

77030

Baylor College of Medicine, Houston

78229

Synexus Clinical Research US, Inc. - San Antonio, San Antonio

80045

Anschutz Health and Wellness Center University of Colorado Anschutz Medical Campus, Aurora

84132

University of Utah, Salt Lake City

85206

Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC, Mesa

85224

Synexus Clinical Research US, Inc. - Phoenix Southeast, Chandler

85258

Honor Health Research Institute, Scottsdale

89075

University of Ulm, Ulm

89106

Impact Clinical Trials, Las Vegas

90017

Axis Clinical Trials-Downtown, Los Angeles

90036

Axis Clinical Trials Headquarters, Los Angeles

92108

San Diego Wake Research, San Diego

97405

Service de pédiatrie CHU de la Réunion - Hôpital Félix Guyon, Saint-Denis

98101

Seattle Children's Research Institute, Seattle

04102

Maine Medical Partners, Portland

01107

Baystate Medical Center, Springfield

37212-3157

Vanderbilt University School of Medicine, Nashville

T6G 2E1

University of Alberta, Edmonton

04103

University of Leipzig, Leipzig

3015 CE

Erasmus MC, Rotterdam

65 28009

Hospital Infantil Universitario Niño Jesús, Madrid

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

CB2 0QQ

Addenbrooke's Hospital, Cambridge

W12 0NN

Hammersmith Hospital, London

Unknown

Hammersmith Hospital, London

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT03013543 - Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Biotech Hunter | Biotech Hunter